US Patent 7968098 HLA-A24-binding KIF-derived peptide
Patent 7968098 was granted and assigned to Kurume University on June, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+413 characters)
Article
Patent abstract
An object of the invention is to provide a peptide derived from a glioma-associated antigen being useful for the specific immunotherapy for glioma patients. The invention provides a KIF-derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of glioma.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Kyogo Itoh0
Mamoru Harada0
Ryuya Yamanaka0
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07968098 HLA-A24-binding KIF-derived peptide US Patent 7968098 HLA-A24-binding KIF-derived peptide
Infobox
Patent Number
079680980
Patent Number
79680980
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079680980
Date of Patent
June 28, 2011
0Patent Application Number
123099500
Date Filed
August 3, 2007
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07968098 HLA-A24-binding KIF-derived peptide
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07968098
Date of patent
June 28, 2011
Patent application number
12309950
Date Filed
August 3, 2007
Patent primary examiner
Find more entities like US Patent 7968098 HLA-A24-binding KIF-derived peptide
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.